ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 27 NOVEMBER 2025 at 9.00 EET 71,498 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 71,498 A shares have been converted into 71,498 B shares. The conversion has been entered into the Trade Register on 27 November 2025. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consi ...

Company Overview - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience in developing, manufacturing, and marketing human and veterinary pharmaceuticals as well as active pharmaceutical ingredients [2] - The company has a diverse portfolio that includes proprietary and generic medicines, as well as consumer health products, focusing on oncology and pain as core therapy areas in its pharmaceutical R&D [2] - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] Share Conversion - A total of 49,164 A shares of Orion Corporation have been converted into B shares, with the conversion recorded in the Trade Register on 24 October 2025 [1] - Following the conversion, the total number of shares in Orion Corporation is 141,134,278, consisting of 31,841,817 A shares and 109,292,461 B shares [1] - The total number of votes associated with the company's shares after the conversion is 746,128,801 [1]

Core Viewpoint - Orion Corporation is set to publish its Interim Report for January–September 2025 on 28 October 2025, with a webcast scheduled for the same day to discuss the report [1][2]. Group 1: Financial Reporting - The Interim Report will be released at approximately 12.00 noon EET on 28 October 2025 [1]. - A live webcast and conference call for analysts, investors, and media representatives will take place at 13.30 EET on the same day [2]. Group 2: Webcast Details - The live webcast link will be available on Orion's website, and a recording will be accessible later the same day [2]. - Participants can join the conference call by registering through a provided link, with access details shared post-registration [3]. Group 3: Company Background - Orion is a Nordic pharmaceutical company with over a hundred years of experience, focusing on developing, manufacturing, and marketing human and veterinary pharmaceuticals [5]. - The company reported net sales of EUR 1,542 million in 2024 and employs approximately 3,700 professionals globally [5].

Group 1 - Orion Corporation has converted 80,802 A shares into B shares, with the conversion recorded on September 19, 2025 [1] - After the conversion, the total number of shares in Orion Corporation is 141,134,278, consisting of 31,890,981 A shares and 109,243,297 B shares [1] - The total number of votes for the company's shares after the conversion is 747,062,917 [1] Group 2 - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on human and veterinary pharmaceuticals and active pharmaceutical ingredients [2] - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] - The core therapy areas of Orion's pharmaceutical R&D include oncology and pain, with proprietary products developed for treating cancer, neurological diseases, and respiratory diseases [2]

Group 1 - Orion Corporation has converted 337,000 A shares into B shares, with the conversion recorded on August 20, 2025 [1] - After the conversion, the total number of shares in Orion Corporation is 141,134,278, consisting of 31,971,783 A shares and 109,162,495 B shares [1] - The total number of votes for the company's shares after the conversion is 748,598,155 [1] Group 2 - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on human and veterinary pharmaceuticals and active pharmaceutical ingredients [2] - The company reported net sales of EUR 1,542 million in 2024 and employs approximately 3,700 professionals globally [2] - Orion's core therapy areas in pharmaceutical R&D include oncology and pain, with proprietary products developed for treating cancer, neurological diseases, and respiratory diseases [2]

Financial Reporting Schedule - Orion Corporation will publish its Financial Statement Release for 2025 on Thursday, 12 February 2026 [1] - The Interim Reports and Half-Year Financial Report for 2026 will be published on the following dates: - Interim Report for January-March 2026: Thursday, 23 April 2026 - Half-Year Financial Report for January-June 2026: Friday, 17 July 2026 - Interim Report for January-September 2026: Wednesday, 28 October 2026 [1] Annual General Meeting - The Annual General Meeting is scheduled for Tuesday, 24 March 2026 [2] Company Overview - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on developing, manufacturing, and marketing human and veterinary pharmaceuticals and active pharmaceutical ingredients [2] - The company has a diverse portfolio that includes proprietary and generic medicines as well as consumer health products, with core therapy areas in oncology and pain [2] - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] - Orion's A and B shares are listed on Nasdaq Helsinki [2]

Group 1 - Orion Corporation has converted 141,959 A shares into B shares, with the conversion recorded on June 23, 2025 [1] - After the conversion, the total number of shares in Orion Corporation is 141,134,278, consisting of 32,308,783 A shares and 108,825,495 B shares [1] - The total number of votes for the company's shares after the conversion is 755,001,155 [1] Group 2 - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on human and veterinary pharmaceuticals and active pharmaceutical ingredients [2] - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] - The core therapy areas of Orion's pharmaceutical R&D include oncology and pain, with proprietary products developed for treating cancer, neurological diseases, and respiratory diseases [2]

Group 1 - Orion Corporation has received a notification regarding transactions made by its board member, Karen Lykke Sørensen, under the Market Abuse Regulation [1] - The transaction involved the receipt of a share-based incentive, with a volume of 415 shares at a unit price of 0 EUR [1] - In 2024, Orion's net sales amounted to EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] Group 2 - Orion Corporation operates as a Nordic pharmaceutical company, developing, manufacturing, and marketing both human and veterinary pharmaceuticals [2] - The company has a diverse portfolio that includes proprietary and generic medicines, as well as consumer health products, focusing on oncology and pain in its pharmaceutical R&D [2] - Orion's shares are listed on Nasdaq Helsinki, indicating its presence in the public market [2]

Group 1 - Orion Corporation has received a notification regarding transactions made by its board member Kari Jussi Aho, specifically concerning share-based incentives [1] - The transaction occurred on April 30, 2025, involving 415 shares at a unit price of 0 EUR, indicating a receipt of a share-based incentive [1] - Orion Corporation is a Nordic pharmaceutical company with a history of over a hundred years, focusing on human and veterinary pharmaceuticals, and has a diverse portfolio including proprietary and generic medicines [2] Group 2 - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] - The core therapy areas of Orion's pharmaceutical R&D include oncology and pain management, with proprietary products aimed at treating cancer, neurological diseases, and respiratory diseases [2] - Orion's shares are listed on Nasdaq Helsinki, indicating its presence in the public market [2]

Company Overview - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience in developing, manufacturing, and marketing human and veterinary pharmaceuticals and active pharmaceutical ingredients [2] - The company has a diverse portfolio that includes proprietary and generic medicines as well as consumer health products, focusing on oncology and pain as core therapy areas in its pharmaceutical R&D [2] - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] Managerial Transactions - Eija Ronkainen, a member of the Board and Deputy member, made an initial notification regarding a transaction involving shares of Orion Corporation [1] - The transaction occurred on April 30, 2025, involving the receipt of a share-based incentive, with a volume of 415 shares at a unit price of 0 EUR [1] - The aggregated transaction also reported a volume of 415 shares with a volume-weighted average price of 0 EUR [1]